Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly

European Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2001, Pages 411-418

  Cheung, Wing ^a   Minton, Neil ^b   Gunawardena, Kulasiri ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Chiltern House   (United Kingdom)

^c Stoke Poges   (United Kingdom)

Author keywords

Epoetin alfa; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; HALF LIFE TIME; HUMAN; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; ANEMIA; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOETIN ALFA; ERYTHROCYTE COUNT; FEMALE; HALF-LIFE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; RETICULOCYTE COUNT;

EID: 0035433756     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100324     Document Type: Article

References (17)

1. Littlewood TJ. Bajelta E. Mortier JWR. Vercammen E. Rapoport B. for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hématologie parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
2. Démetri GD. Kris M. Wade J. Degos L. Cella D. for the Procrit Study Group (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412 3425
3. Glaspy J. Bukowski R. Steinberg D, Taylor C. Tchekmedyian S. Vadhan-Raj S. for the Procrit Study Group (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218 1234
4. Case DC Jr. Bukowski RM. Carey RW. et al (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer lust 85:801-806
5. Ludwig H. Fritz E, Kotzmann H. Höcker P. Gisslinger H. Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693- 1699
6. Abels R (1993) Erythropoietin for anaemia in cancer patients. Em- J Cancer 29A[Suppl 2]:S2-S8
7. Ludwig H, Sundal E. Pecherstorler M, et al (1995) Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76:2319 2329
8. Leitgeh C. Pecherstorler M. Frit/ H, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recomhinant human erythropoietin. Cancer 73:2535 2542
9. Cheung WK. Goon BL. Guilfovjc MC.(1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64:412 423
10. Gabrilove JL, Cleeland CS. Livingston RB. Sarokhan B. Winer E, Einhorn LW (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life similar to three-times-weekh dosing, i Clin Oncol 19:2875 2XX2
11. Shasha D. George MJ, Harrison LB (2000) Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Blood 96:434a
12. Kraul/ SB. üoldwasser E (19X4) Specific hinding of enthropoietin to spleen cells infected with the anemia strain of friend virus. Proc Natl Acad Sci U S A 81:7574-7578
13. Sawyer ST. Krantz SB. Goldwasser E (1987) Binding and receptor-mediated endocytosis of erylhropoietin in Friend virus-infected ervthroid cells. .1 Biol C'hem 262:5554-5562
14. Spivak JL. Pham T. Isaacs M. Hankins WD (1991) Erythropoietin is both a mitogen and a survival factor. Blood 77:1228-1233
15. Ding R. Fies T. Braun A. Kurt/ A. Scharer K (1992) Dose-response relationship in children with chronic renal failure CRF treated by erythropoietin (EPO) applied subcutaneous!). Pediatr Nephrol 6:C169
16. Besarab A (1993) Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration. Am J Kidney Dis 22[Suppl 1]:13-22
17. Gabrilove JL. Einhorn LH. ('Iceland C'S. Livingston KB. Winer E (1999) Once-weekly dosing of epoetin alfa increases hemoglobin (Hb) and improves quality of life (QOL) in patients with hématologie malignancies (abstract I. Blood 94[Suppl l]:400a